Semaglutide denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Semaglutide as Experimental

Semaglutide carries FDA approval for specific indications including type 2 diabetes management and chronic weight management in adults meeting defined criteria. An "experimental" or "investigational" denial from Aetna for semaglutide almost always means one of two things: (1) the drug is being prescribed for an indication or patient population not currently covered by Aetna's clinical policy — for example, an emerging indication that is FDA-approved but where Aetna's medical policy has not yet been updated, or (2) the documentation submitted did not establish that the request falls within the FDA-approved, covered use. This denial is strongly contestable when the use is within the approved labeling.

## Why This Denial Is Appealable

An experimental/investigational label applied to a drug with a relevant FDA-approved indication is legally and clinically challengeable. Aetna's clinical policy cannot define as experimental a use that the FDA has approved and that major medical societies support. Independent external reviewers routinely overturn experimental denials when the evidence base is well-established.

## Your Federal Appeal Rights

• Internal appeal: Request a copy of the specific Aetna clinical policy invoked. Challenge the policy directly if it conflicts with the FDA label or current evidence-based guidelines from the relevant major medical society.
• ACA §2719 / External Review: After an adverse internal decision, you generally have approximately four months to request independent external review. External reviewers apply objective medical evidence standards and are not bound by Aetna's internal policy definitions.
• ERISA §503 (employer plans): Entitles you to the full claim file and written explanation of the experimental determination criteria.
• Expedited review: Available if the clinical situation is urgent.

## Appeal Timeline

1. Obtain the denial letter and the specific Aetna clinical policy document cited. 2. Confirm with your prescriber that the requested use is within the FDA-approved indication. 3. Gather guideline-organization support (reference the applicable professional society without citing specific numbers). 4. File internal appeal; escalate to external review if upheld.

## Documentation to Gather

• FDA prescribing information: Confirming the approved indication that applies to this patient.
• Diagnosis and eligibility documentation: Chart notes, lab results, and assessments establishing that the patient falls within the FDA-approved population for this use.
• Prescriber letter: Explaining the evidence basis for the prescription, the guideline-organization support, and why the use is not experimental.
• Guideline reference: A citation to the relevant professional society guideline (without specific numbers) supporting the prescribed use.
• Prior treatment history: Particularly relevant for weight management indications, where documentation of prior interventions may be required.

## Criteria-Mapping Structure

Place Aetna's experimental/investigational criteria in the left column of a table. In the right column, document the FDA label excerpt, diagnosis confirmation, and guideline reference that refutes each experimental criterion. Ensure the prescriber's letter mirrors this structure so that both documents reinforce each other.